Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
Aim: The aim was to compare patients′ morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC). Patients and Methods: This was a...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Urology Annals |
Subjects: | |
Online Access: | http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=1;spage=7;epage=12;aulast=Inamoto |
id |
doaj-9e9290fad6f94f259a636fbd825a0bb1 |
---|---|
record_format |
Article |
spelling |
doaj-9e9290fad6f94f259a636fbd825a0bb12020-11-24T23:08:37ZengWolters Kluwer Medknow PublicationsUrology Annals0974-77960974-78342013-01-015171210.4103/0974-7796.106873Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparisonTeruo InamotoTakanobu UbaiTakeshi NishidaYutaka FujisueYoji KatsuokaHaruhito AzumaAim: The aim was to compare patients′ morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC). Patients and Methods: This was a randomized, active-controlled, open-label, monocenter study. Thirty-eight, NMIBC patients were treated sequentially, in a random order, with low-dose Tokyo 172 strain and regular dose Connaught strain, receiving each therapy for 6 weeks. A total of 18 and 20 patients were randomly assigned to a Tokyo 172 strain arm and a Connaught strain arm, respectively. Complication, morbidity, and recurrence-free survival (RFS) after each treatment were compared. Results: There was no significant difference in the 1-year RFS rate in patients treated with Tokyo 172 strain and Connaught strain (72.2% vs. 83.5%, respectively; P = 0.698). There were no significant differences in adverse events between the arms. Severe adverse events (>Grade 3) were seen in 15% of the Connaught strain group while no severe adverse events were observed as a result of Tokyo 172 strain. Conclusion: Our results indicated that low-dose Tokyo 172 strain decreased adverse events although it was not significant, and the RFS difference was not statistically significant between the two arms. Further investigation is warranted.http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=1;spage=7;epage=12;aulast=InamotoBacillus Calmette-Guérinbladder cancerintravesical instillationTokyo 172 strain |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Teruo Inamoto Takanobu Ubai Takeshi Nishida Yutaka Fujisue Yoji Katsuoka Haruhito Azuma |
spellingShingle |
Teruo Inamoto Takanobu Ubai Takeshi Nishida Yutaka Fujisue Yoji Katsuoka Haruhito Azuma Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison Urology Annals Bacillus Calmette-Guérin bladder cancer intravesical instillation Tokyo 172 strain |
author_facet |
Teruo Inamoto Takanobu Ubai Takeshi Nishida Yutaka Fujisue Yoji Katsuoka Haruhito Azuma |
author_sort |
Teruo Inamoto |
title |
Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison |
title_short |
Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison |
title_full |
Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison |
title_fullStr |
Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison |
title_full_unstemmed |
Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison |
title_sort |
comparable effect with minimal morbidity of low-dose tokyo 172 strain compared with regular dose connaught strain as an intravesical bacillus calmette-guérin prophylaxis in nonmuscle invasive bladder cancer: results of a randomized prospective comparison |
publisher |
Wolters Kluwer Medknow Publications |
series |
Urology Annals |
issn |
0974-7796 0974-7834 |
publishDate |
2013-01-01 |
description |
Aim: The aim was to compare patients′ morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC).
Patients and Methods: This was a randomized, active-controlled, open-label, monocenter study. Thirty-eight, NMIBC patients were treated sequentially, in a random order, with low-dose Tokyo 172 strain and regular dose Connaught strain, receiving each therapy for 6 weeks. A total of 18 and 20 patients were randomly assigned to a Tokyo 172 strain arm and a Connaught strain arm, respectively. Complication, morbidity, and recurrence-free survival (RFS) after each treatment were compared.
Results: There was no significant difference in the 1-year RFS rate in patients treated with Tokyo 172 strain and Connaught strain (72.2% vs. 83.5%, respectively; P = 0.698). There were no significant differences in adverse events between the arms. Severe adverse events (>Grade 3) were seen in 15% of the Connaught strain group while no severe adverse events were observed as a result of Tokyo 172 strain.
Conclusion: Our results indicated that low-dose Tokyo 172 strain decreased adverse events although it was not significant, and the RFS difference was not statistically significant between the two arms. Further investigation is warranted. |
topic |
Bacillus Calmette-Guérin bladder cancer intravesical instillation Tokyo 172 strain |
url |
http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=1;spage=7;epage=12;aulast=Inamoto |
work_keys_str_mv |
AT teruoinamoto comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison AT takanobuubai comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison AT takeshinishida comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison AT yutakafujisue comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison AT yojikatsuoka comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison AT haruhitoazuma comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison |
_version_ |
1725613249216380928 |